A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD.

Next Previous
Trial Profile

A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
    • 09 Jan 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
    • 23 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top